That is essential, since the method a protein in the human body folds figures out if a pharmaceutical will be able to bind to that protein and work. Simply put, we have to understand how these proteins fold if we desire a drug to work. Historically, this has been an experimental procedure (bleeding edge). Today, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it a lot easier to create drugs that do what they're designed to do. This was an advancement practically no one noticed. However it's going to have extensive ramifications for curing disease. I forecast that Alpha, Fold will be 98% accurate by the end of 2021.
And, naturally, there will be a lot of investment opportunities in this area, too. Moving topics It's going to be a good year for bitcoin. I'm bullish on it in 2021 (jeff brown biotech picks). That stated, I still believe bitcoin will continue to be unstable. We're close to all-time highs. I would not be shocked if it drew back possibly substantially before going higher - genetic sequencing companies jeff brown. I've been covering bitcoin for a very long time now. One of the very first research reports I ever published was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
However at the time of that initial suggestion, I titled my report "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time. We were mainly informing readers. But that's not the big concern anymore. Now we're seeing institutional cash finally take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, niche enterprise. Mass, Mutual is a relied on 170-year-old organization. So think about that. In 5 years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
Which's a big reason I'm bullish on it this year. jeff brown genetic sequencing stock. Regards, Jeff Brown, Editor, The Bleeding Edge I have a perk forecast 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These companies raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I forecast 2021 will be another record year in IPOs. There are so lots of terrific private companies on the edge of hitting the public markets And I have actually been dealing with a brand-new method for you to invest even prior to these companies go public.
This opportunity has been constructing over the last couple of years. I can't wait to inform you all about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Occasion to learn all the details. Go right here to schedule your spot totally free.
Emma Walsh here, managing editor of the Journal. Routine Journal readers know that tech isn't our typical beat (genetic sequencer stock jeff brown). And when it concerns tech investing, we leave it to the experts. The good news is, we have numerous such specialists in our Rolodex. Our colleague Jeff Brown will recognize to our longtime readers. He is among the most accomplished tech investing professionals we understand (brownstone research stock). In truth, he had a number of triple-digit returns in his Brownstone Research study portfolios in 2015. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to take an appearance at the big picture and predict what's simply around the corner.
That includes things like 5G networks, biotech, synthetic intelligence, and much more. These patterns are experiencing rapid development and producing amazing chances for financiers. I wish to make sure all our readers are prepared for what's next. And with that in mind, let me draw the picture of what I see coming in the next 12 months Our new 5G (fifth-generation) wireless networks are a subject I have actually been covering for years now. brownstone research stock. But regardless of what many readers might believe, this is a trend that's simply starting. Although the COVID-19 pandemic disrupted supply chains last year, an impressive 250 million 5G-enabled gadgets were still sold.
And all of this eventually led to Apple delaying the release of the 5G-enabled i, Phone 12 by 2 months (biotech stock). Losing 2 months of production and sales truly affects the number of 5G gadgets are offered in the calendar year. When you consider all of that, offering 250 million units is amazing. More significantly, the hold-ups triggered by the pandemic produced a lots of bottled-up demand. Which demand is now going to be pushed into 2021. In reality, I forecast that more than 500 million 5G gadgets will be delivered in 2021 - genetic sequencing companies jeff brown. And that's not my only 5G forecast When I've talked about 5G in the past, I've explained its 3 various stages.
In Stage Two, 5G gadgets go on sale. 5G phones and other items begin to reach customers. And in Phase Three, 5G services begin to be offered (jeff brown stock predictions). That's when we begin to see applications running on 5G networks. Think about things like enormous multiplayer games over a mobile phone. That's not possible with 4G. It will be with 5G. And my second 5G forecast for 2021 is that we will start Stage Three by this summer. This begins something of a virtuous cycle: The majority of people don't actually care about the innovation. But they will care if there are amazing applications that can just be accessed with a 5G phone.
That causes more 5G apps being developed. In truth, 5G is going to open a suite of amazing applications: self-driving cars and trucks, the Web of Things, robotic surgical treatment, and more. All of these technologies require 5G. The investment opportunities going forward will be massive. Stepping far from 5G, the next crucial technology I visualize in 2021 is CRISPR genetic editing. CRISPR represents "clustered routinely interspaced short palindromic repeat." It's a mouthful. But it's one of the most exciting advancements in biotechnology. At a high level, CRISPR is an innovation that can edit our genetic makeup as if it were software application.
The program can crash or not operate correctly. CRISPR uses a similar concept but with our hereditary code. "Typos" in our genome can cause illness. CRISPR can remedy these "typos." For many years, CRISPR was mainly a niche technology that wasn't well comprehended. And during that time, there were actually just 3 business running in this area. However things are altering. CRISPR is no longer simply theoretical. We're seeing actual outcomes. We're treating illness and seeing that this technology just works. And as a result, a "2nd crop" of early-stage CRISPR business is going public and delivering unbelievable returns. This whole industry is efficiently a greenfield opportunity.
There's space for numerous business to exist in this area. exponential growth. And there will be more. That's my prediction for CRISPR in 2021. I forecast that 2 or 3 more genetic editing companies will hold their IPOs. Sticking with biotechnology, we are seeing amazing things taking place at the merging of biotech and synthetic intelligence (AI). Google's AI subsidiary, Deep, Mind, just announced at the end of 2020 that its newest Alpha, Fold software can properly predict the folding of a protein based exclusively on its amino acid series with 92. 4% precision. That's essential due to the fact that the way a protein in the human body folds figures out if a pharmaceutical will be able to bind to that protein and be effective.
Historically, this has been an experimental process. But now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it a lot easier to create drugs that do what they're designed to do. And here's my next forecast. I forecast that Alpha, Fold will be 98% precise by the end of 2021. And we will see not just one however numerous drug treatments produced utilizing this technology. This was among those advancements that nearly no one discovered. However it's going to have extensive implications for treating disease. And, of course, there will be a lot of investment opportunities in this area, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That said, I still think bitcoin will continue to be unpredictable. We're close to all-time highs. I would not be shocked if it drew back perhaps substantially before going greater. I've been covering bitcoin for a long period of time now. Among the first research study reports I ever published was on bitcoin - genetic sequencing companies jeff brown. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on investment for anybody who followed my suggestion. But at the time of that initial recommendation, I titled my report, "What's the Big Offer With Bitcoin?" That reveals you where the discussion was at the time.
But nobody is asking that question anymore. Now, we're seeing institutional cash lastly taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, niche business. brownstone research. Mass, Mutual is a 150-year-old institution. So consider that. In 5 years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a huge reason that I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another benefit forecast In 2021, we're going to have another record year in IPOs. One site reports that Jeff Brown deserves about $27. 5 million and declares the details depends on date since February 2021, but we could not separately validate this claim. Provided Jeff Brown's past, he likely has a significant net worth, but we can't hammer down an accurate figure at this minute. Brown is best understood for his sage-like capability to choose winning innovation stocks. He spent more than 25 years investigating innovation business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience offers him an exceptional point of view on the market. He's always on the hunt for new opportunities, and he shares numerous of his finest choices in the Near Future Report.
That's full marks, however it's not absurdly reasoned. Brown has an excellent credibility as a stock-picker, and he successfully forecasted a few of the biggest economic events of the past twenty years. Although he does not appear to release his choices to the general public, the service's success is a direct sign of Brown's stock-picking prowess. No one on Wall Street gets it ideal whenever, however Jeff Brown's accurate predictions have made him legions of dedicated fans. That states a lot about his ability. The Future Report is released by Brownstone Research study, a popular financial research study publisher. Brownstone Research study uses a number of research study services with a variety of expertises - jeff brown top biotech stock 2021.
The business is likewise affiliated with Bonner & Partners, another well-respected research study publisher - jeff brown biotech genome sequencing. On its site, Brownstone states its mission is to offer retail investors with professional-grade research: "For too long, the very best financial investment research study has actually not been available to specific financiers. It has actually been normally scheduled for financial investment banks, hedge funds, personal equity, and high-net-worth clients. jeff brown genetic sequencer stock. The mission of Brownstone Research is to make that sort of proprietary research study offered to any investors seeking to acquire an edge in the marketplaces. The goal is simple to provide unique and rewarding financial investment research study discovered nowhere else." -Brownstone Research study site excerpt from the Jeff Brown is the founder of Brownstone Research study, and he likewise works as the company's Chief Financial investment Analyst.
With Brown guiding the ship, Brownstone Research is a powerhouse publisher with lots to offer its customers. After decades of steady success at the helm of top-tier business like Tesla and Space, X, Elon Musk is a household name throughout many of America. If you know even a little bit about the marketplace, you know that he has a track record as a King Midas of sorts. jeff brown 1 biotech. Everything he touches relies on gold! Jeff is well mindful of Elon Musk's executive expertise, so he constantly has an eye out for the Silicon Valley rock star's next move. This time, Jeff has an early lead on Elon's next big task.
In truth, Brown believes S.A.V. melania trump. could be "the greatest pattern of the 2020s, and he's not alone. Have a look at these quotes from other popular S.A.V. bulls: Elon's next big act will be weding two innovative technologies: synthetic intelligence and electric vehicles. Musk hopes the combination will assist him develop the first fully-autonomous, self-driving cars ever. It's nothing except the vehicle market's Holy Grail. As you understand, electric vehicles and self-driving cars and truck stocks have been huge this year, however the Wall Street device has actually been huge on buzz without much concrete outcome. In spite of a drastic boost in competition over the past few years, Brown still thinks Musk has the best possibility of putting everything together.
tech might be the magic string that ties everything together. S.A.V. represents Shared Autonomous Car, and it could be the future of transportation. Essentially, this innovation would enable you to rent out your automobile as a self-governing, self-driving taxi when you're not using it. You merely leave the vehicle and press a button on an app that tells the vehicle to "sign up with the fleet." Next thing you know, you're relaxing on your couch while your vehicle shuttles ride-sharers around town. Best of all, you get to keep a significant chunk of the earnings. It sounds outrageous, however it could be closed than you believe.